Lv1
20 积分 2021-09-27 加入
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
4天前
已完结
ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours
24天前
已完结
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
3个月前
已完结
Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial
8个月前
已完结
皖公网安备34019202002308
